PEG-MGF vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | PEG-MGF | Substance P |
|---|---|---|
| Mechanism | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |